Free Trial

OmniAb, Inc. (NASDAQ:OABI) CEO Matthew W. Foehr Sells 13,964 Shares of Stock

OmniAb logo with Medical background

OmniAb, Inc. (NASDAQ:OABI - Get Free Report) CEO Matthew W. Foehr sold 13,964 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $3.68, for a total transaction of $51,387.52. Following the completion of the sale, the chief executive officer now owns 3,798,682 shares in the company, valued at $13,979,149.76. This represents a 0.37 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

OmniAb Trading Down 5.3 %

OABI stock traded down $0.21 during midday trading on Friday, reaching $3.68. 420,621 shares of the company's stock traded hands, compared to its average volume of 500,445. OmniAb, Inc. has a 52-week low of $3.10 and a 52-week high of $6.55. The stock has a market cap of $518.98 million, a P/E ratio of -5.98 and a beta of -0.12. The stock's 50-day moving average is $3.49 and its 200 day moving average is $3.91.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on OABI shares. HC Wainwright reissued a "buy" rating and set a $11.00 price target on shares of OmniAb in a report on Thursday, November 14th. Benchmark reissued a "buy" rating and issued a $8.00 target price on shares of OmniAb in a report on Thursday, November 14th.

Read Our Latest Research Report on OmniAb

Institutional Investors Weigh In On OmniAb

Hedge funds have recently modified their holdings of the business. Hsbc Holdings PLC bought a new position in OmniAb in the 4th quarter worth $38,000. Choreo LLC purchased a new stake in OmniAb in the fourth quarter worth about $41,000. Rangeley Capital LLC bought a new position in shares of OmniAb in the fourth quarter worth about $41,000. CWC Advisors LLC. bought a new position in shares of OmniAb in the third quarter worth about $54,000. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of OmniAb during the 4th quarter valued at about $49,000. Institutional investors own 72.08% of the company's stock.

About OmniAb

(Get Free Report)

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.

Recommended Stories

Insider Buying and Selling by Quarter for OmniAb (NASDAQ:OABI)

Should You Invest $1,000 in OmniAb Right Now?

Before you consider OmniAb, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.

While OmniAb currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines